文献速递类风湿关节炎

免疫血栓形成增强是类风湿关节炎中JAK抑制剂相关高凝状态的关键机制

Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2025-09-26

研究探讨JAK抑制剂是否增强类风湿关节炎(RA)中免疫细胞驱动的凝血(免疫血栓形成)。外周血白细胞经不同JAK抑制剂处理后,托法替布联合LPS显著加速血浆凝块形成,且呈组织因子途径依赖,并伴免疫血栓相关细胞因子升高;选择性JAK3抑制未重现促血栓效应。

要点

  • 托法替布联合LPS处理的外周血白细胞条件培养基较单用LPS显著加速凝块形成,且为组织因子途径依赖。
  • 活动性RA患者外周血白细胞的免疫血栓潜能显著高于低疾病活动度者,尽管基线细胞因子水平相当。
  • JAK1/酪氨酸激酶2依赖效应与促血栓相关,选择性JAK3抑制未重现促血栓效应。

核心结论

  • 免疫血栓形成可为RA中JAK抑制剂相关静脉血栓栓塞提供新的解释。

研究设计与样本

  • 研究纳入RA患者和健康对照的外周血白细胞,经不同类别JAK抑制剂处理后再以TLR4(LPS)或TLR3(poly(I:C))激动剂刺激,条件上清用于血浆浊度试验评估凝块形成与溶解动力学,并用bulk RNA测序、ELISA和珠基免疫分析探索机制。

主要发现

  • 浊度分析显示,LPS加托法替布处理的外周血白细胞条件培养基较单用LPS显著加速凝块形成,该效应为组织因子途径依赖,并伴肿瘤坏死因子α、白细胞介素(IL)-1β和IL-6等免疫血栓相关细胞因子升高。
  • 活动性RA患者的外周血白细胞免疫血栓潜能显著高于低疾病活动度患者,尽管基线细胞因子水平相当。
  • RNA测序显示托法替布/LPS处理的外周血白细胞存在显著通路富集,包括核因子(NF)-κB通路激活、组织因子表达增加以及蛋白S等抗凝因子水平降低。
  • 5种JAK疗法的药理学抑制试验提示JAK1/酪氨酸激酶2依赖效应与血栓增加相关,而选择性JAK3抑制未重现促血栓效应。
  • 伴有JAK相关肺栓塞的RA患者中,4/6(67%)显示与免疫血栓形成相符的间质改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Venous thromboembolism (VTE), following Janus kinase inhibitors treatment (JAKi), is poorly understood in rheumatoid arthritis (RA). We investigated whether JAKi augmented immune cell-driven clotting or immunothrombosis in RA. METHODS: Peripheral blood leukocytes (PBLs) isolated from patients with RA and healthy controls were treated with various JAKi classes, before stimulation with Toll-like receptor (TLR)-4 (lipopolysaccharide [LPS]) or TLR3 (polyinosinic-polycytidylic acid-poly (I:C)) agonists. Conditioned supernatants were used in plasma turbidity assays to evaluate clot formation and lysis dynamics, while bulk RNA sequencing, enzyme-linked immunosorbent assay, and bead-based immunoassays were used to explore immunothrombosis mechanisms. RESULTS: Turbidity analyses showed that conditioned media from PBLs treated with LPS and tofacitinib significantly accelerated clot formation when compared to LPS alone, and this effect was tissue factor pathway dependent and accompanied by elevations in immunothrombotic cytokines, including tumour necrosis factor α, interleukin (IL)-1β, and IL-6. PBLs from patients with active RA exhibited significantly greater immunothrombotic potential compared to those with low disease activity, despite comparable baseline cytokine levels. RNA sequencing analysis revealed significant pathway enrichment in tofacitinib/LPS-treated PBLs, including activation of Nuclear Factor (NF)-κB pathways, increased tissue factor expression, and reduced levels of anticoagulant factors such as protein S. Pharmacological inhibition assays with 5 JAK therapies suggested that JAK1/tyrosine kinase 2-dependent effect underscored increased thrombosis but selective JAK3 inhibition did not reproduce the prothrombotic effects. Finally, patients with RA with JAK-associated pulmonary embolism showed interstitial changes compatible with immunothrombosis in 4/6 (67%). CONCLUSIONS: Immunothrombosis offers a novel explanation for JAKi-associated VTE in RA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. David P, Macleod T, Altaie A, et al. Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis. Ann Rheum Dis. 2025. PMID: 41006174. doi:10.1016/j.ard.2025.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。